tetano
Editor, Senior Moderator
J Public Health Policy. 2018 Jul 16. doi: 10.1057/s41271-018-0138-8. [Epub ahead of print]
[h=1]What treating Ebola means for pandemic influenza.[/h] Fedson DS[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Almost all new treatments being developed for the next influenza pandemic target the virus. During the Ebola crisis in West Africa, patients were treated with an inexpensive generic statin/angiotensin receptor blocker combination that appeared to greatly improve survival. These drugs target the host response, not the virus, and probably reverse endothelial dysfunction. Scientists and health officials have shown little interest in this idea. Yet, during the early months of the next pandemic, vaccines will be unavailable and treatment options will be limited. Physicians should be prepared to undertake clinical trials of widely available generic drugs to determine whether they improve survival in patients with seasonal influenza, other emerging virus diseases, and other forms of acute critical illness. Public health officials should give these studies their strong support. If successful, they will suggest a 'bottom up' approach to patient care that could be implemented worldwide on the first pandemic day.
[h=4]KEYWORDS:[/h] Angiotensin receptor blockers; Ebola; Emerging virus diseases; Endothelial dysfunction; Host response; Pandemic influenza; Statins
PMID: 30013135 DOI: 10.1057/s41271-018-0138-8
[h=1]What treating Ebola means for pandemic influenza.[/h] Fedson DS[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Almost all new treatments being developed for the next influenza pandemic target the virus. During the Ebola crisis in West Africa, patients were treated with an inexpensive generic statin/angiotensin receptor blocker combination that appeared to greatly improve survival. These drugs target the host response, not the virus, and probably reverse endothelial dysfunction. Scientists and health officials have shown little interest in this idea. Yet, during the early months of the next pandemic, vaccines will be unavailable and treatment options will be limited. Physicians should be prepared to undertake clinical trials of widely available generic drugs to determine whether they improve survival in patients with seasonal influenza, other emerging virus diseases, and other forms of acute critical illness. Public health officials should give these studies their strong support. If successful, they will suggest a 'bottom up' approach to patient care that could be implemented worldwide on the first pandemic day.
[h=4]KEYWORDS:[/h] Angiotensin receptor blockers; Ebola; Emerging virus diseases; Endothelial dysfunction; Host response; Pandemic influenza; Statins
PMID: 30013135 DOI: 10.1057/s41271-018-0138-8